ArticleDiscover oncology2025
hsa-let-7b-5p/TMPO-AS1-mediated ceRNA networks are linked to poor prognosis for lung cancer patients with FOXM1/MAD2L1 axis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Identification of novel ceRNA networks associated with system hemostasis and their prognostic implication in lung squamous cell carcinoma.Journal of thrombosis and thrombolysis · 2026Article
- The MAD2L1-FOXM1 axis negatively regulates CD4⁺ T cell and macrophages infiltration in lung adenocarcinoma.Discover oncology · 2026Article
- Integrative Meta-Analysis and WGCNA Reveal Candidate Diagnostic Hub Genes in Clear Cell Carcinoma.International journal of cell biology · 2026Article
- Long noncoding RNA TMPO-AS1 upregulates chromosomal passenger complex expression to promote cell proliferation in lung cancer via sponging microRNA let-7b-5p.Cell division · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMAD2L1, a spindle assembly checkpoint molecule, is associated in cancer cell proliferation and carcinogenesis, although its ceRNA network is unknown.
methodsInitially, patient's survivability associated with the gene expression was analysed by using the Kaplan-Meier plotter database. Here, we used several TCGA databases such as UALCAN, OncoDB, ENCORI, lung cancer explorer, GEPIA2, TCGAnalyzer, and CancerMIRNome to identify differential mRNA, miRNA, and lncRNA expression. The Enrichr database was utilized to identify the transcription factor regulating MAD2L1, which was then correlated with miRNA and lncRNA, forming the ceRNA network using the miRNet database. Database miRWalk and RNA22v2 were used to predict the folding energy and binding affinity between the MAD2L1 and miRNA. TIMER and TIMER 2.0 databases were incorporated to analyse the tumor infiltrating immune cells in LUAD.
resultsThe study found that overexpression of MAD2L1 in lung cancer patients is a high-risk factor for lung adenocarcinoma (LUAD) (HR = 1.34, P = 0.001), particularly in smoker females (HR = 1.61, P = 0.018). The study revealed MAD2L1 overexpression in LUAD cases, with a fold change of 8.7, and a strong positive correlation between RNA and protein expression levels by Cancer Proteome (R = 0.764). The study identified regulatory molecules of MAD2L1 such as transcription factor FOXM1 (R = 0.770), and lncRNA TMPO-AS1 (R = 0.565) as positively correlated with MAD2L1, while miRNA hsa-let-7b-5p, negatively correlated with MAD2L1 (R = - 0.314), FOXM1 (R = - 0.393), and TMPO-AS1 (R = - 0.277). The study suggests that TMPO-AS1 suppresses tumor suppression activity of let-7b-5p and targeting hsa-let-7b-5p could regulate MAD2L1, FOXM1 and lncRNA expression levels in LUAD. Additionally, a strong folding and binding energy was identified between the MAD2L1 gene and hsa-let-7b-5p. After analyzing the tumor microenvironment, we found that CD4+ T cells and B cells negatively correlate with the overexpression of MAD2L1.
conclusionThe study indicates that MAD2L1 is overexpressed in females with LUAD, highlighting its potential as a molecular classifier and prognostic biomarker, and introduces a novel regulatory ceRNA network.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.